Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7747081 | 1.00 | MAOB (0.50) | MAOBKDM4EPOLBKMT2ATAAR1 | |
| Hydrochloric Acid SCHEMBL5702977 | 0.98 | MAOB (0.49) | MAOBKDM4EPOLBKMT2ATAAR1 | |
| Hydrochloric Acid SCHEMBL5702982 | 0.98 | MAOB (0.49) | MAOBKDM4EPOLBKMT2ATAAR1 | |
| SCHEMBL17044401 | 0.86 | LMNA (0.49) | MAOBKDM4EPOLBKMT2ATAAR1 | |
| SCHEMBL17044403 | 0.86 | LMNA (0.49) | MAOBKDM4EPOLBKMT2ATAAR1 | |
| Hydrochloric Acid SCHEMBL6511737 | 0.85 | LMNA (0.48) | MAOBKDM4EPOLBKMT2ATAAR1 | |
| Hydrochloric Acid SCHEMBL6511744 | 0.85 | LMNA (0.48) | MAOBKDM4EPOLBKMT2ATAAR1 | |
| SCHEMBL31105778 | 0.84 | MAOB (0.41) | MAOBKDM4EPOLBKMT2ATAAR1 | |
| SCHEMBL7748759 | 0.83 | MAOB (0.74) | MAOBPOLBKMT2ALMNANPC1 | |
| SCHEMBL7748756 | 0.83 | MAOB (0.74) | MAOBPOLBKMT2ALMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | HCRTR2, HCRTR1, NPSR1 | MAOB 1364/4885KDM4E 1568/4885POLB 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.